1. All Products
  2. DORA - Oral drugs
  3. NEVIRAPINE (NVP), 50mg/5ml, oral susp., 240ml, bot.
Public Pricelist

NEVIRAPINE (NVP), 50mg/5ml, oral susp., 240ml, bot.

https://medicalguidelines.msf.org/en/node/447
https://unicat.msf.org/cat/product/12195
STD DORANEVI1S2

Valid Article

Former Code(s): -X DORAZBD0406
Article is intended to be used with children (<12 years) ONLY.
6.4.2.2 - Non-nucleoside reverse transcriptase inhibitors
Classification of the medicines in groups and subgroups according to their therapeutic use. The classification used by MSF is based on the WHO Model List of Essential Medicines.
J05AG01
Anatomical Therapeutic Chemical Classification according to WHOCC
PM
The order of this product needs to be justified and is only acceptable under certain conditions.
1525
Thermosensitive codes are defined for storage and transportation temperature requirements of the products.
OC subscriptions: included in supply or field order tools (e.g. UniField)
SC subscriptions: included in supply or field tools
OC validations: approved for procurement and use by an OC for international or local orders specifying context and activity in Medical Standard Lists (MSL)

This combination does not exist.

Add article to list

   
Create Cancel

Add Kit To Wishlist

   
Create Cancel

NEVIRAPINE (NVP)

Therapeutic Action

Antiretroviral, non-nucleoside reverse transcriptase inhibitor (NNRTI)

Indications

Neonatal ARV prophylaxis of mother-to-child transmission (PMTCT) in high-risk HIV-exposed neonates from 6 weeks of age.

Nevirapine is no longer part of the preferred treatment regimens for HIV infection.

Some restricted information has been hidden. Sign in to see this information

Instructions for use

The choice between the oral suspension and the dispersible tablet will depend on the availability when ordering.

The tablet is to be dispersed in about 5 ml of water immediately before administration.

Storage

  • Below 25ºC
  • After opening, the oral suspension keeps for 2 months maximum.